Get started
Author

Sangita M. Baxi

Observed names: Baxi, Sangita, Baxi, Sangita M, Baxi, Sangita M., S M Baxi, S.M. BAXI, Sangita Baxi, Sangita M Baxi
Observed institutions: RAND Corporation, Mayo Clinic, United States Department of Defense, RAND School of Public Policy, University of California, Los Angeles, University of California, San Francisco, Pfizer (United States), VA Greater Los Angeles Healthcare System, United States Navy, Defense and Veterans Brain Injury Center, University of California, Berkeley
ORCID: 0000-0001-9476-3831
Observed ORCID: 0000-0001-9476-3831
OpenAlex ID: A5010409591
Impact of Project ECHO Models of Medical Tele-Education: a Systematic Review
2019 · Ryan K. McBain, Jessica L. Sousa, et al. · Journal of General Internal Medicine · 197
PDF
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
2012 · Timothy S. Fisher, Cris Kamperschroer, et al. · Cancer Immunology Immunotherapy · 167
Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses
2005 · W.R. GOULD, S.M. BAXI, et al. · Journal of Thrombosis and Haemostasis · 119
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
2016 · Hengmiao Cheng, Sajiv K. Nair, et al. · Journal of Medicinal Chemistry · 96
miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells
2013 · Rounak Nassirpour, Pramod P. Mehta, et al. · PLoS ONE · 92
PDF
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
2012 · Hengmiao Cheng, Chunze Li, et al. · ACS Medicinal Chemistry Letters · 86
Mindfulness meditation for workplace wellness: An evidence map
2019 · Lara G. Hilton, Nell J. Marshall, et al. · Work · 77
PDF
Radiation Therapy for Brain Metastases: A Systematic Review
2021 · Adam Garsa, Julie K. Jang, et al. · Practical Radiation Oncology · 42
Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
2013 · Marlena Walls, Sangita M. Baxi, et al. · Clinical Cancer Research · 34
PDF
Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90
2011 · Pramod P. Mehta, Pamela Whalen, et al. · Clinical Cancer Research · 34
Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)
2011 · Sean T. Murphy, Gordon Alton, et al. · Journal of Medicinal Chemistry · 32
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer's Treatment
2019 · Jodi Liu, Jakub Hlavka, et al. · RAND Corporation eBooks · 28
Iliac Venous Stenting
2007 · Robert D. McBane, Robert J. Leadley, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 28
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
2019 · Sangita M. Baxi, Reed Beall, et al. · Globalization and Health · 26
PDF
Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity
2010 · Gang Li, Lianglin Zhang, et al. · Cancer Research · 25
Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro
2006 · W.R. GOULD, T.B. MCCLANAHAN, et al. · Journal of Thrombosis and Haemostasis · 22
Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase
2012 · Noel A. Powell, Jennifer K. Hoffman, et al. · Bioorganic & Medicinal Chemistry Letters · 18
Targeting the mTOR Pathway in Tumor Malignancy
2013 · Hengmiao Cheng, Marlena Walls, et al. · Current Cancer Drug Targets · 15
Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase
2012 · Noel A. Powell, Jennifer K. Hoffman, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells
2012 · Sangita M. Baxi, Wei Tan, et al. · PLoS ONE · 15
PDF
Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV
2017 · and for the Women’s Interagency HIV Study (WIHS), S M Baxi, et al. · The Pharmacogenomics Journal · 12
An evidence map of randomised controlled trials evaluating genetic therapies
2020 · Eric A. Apaydin, Andrea S. Richardson, et al. · BMJ Evidence-Based Medicine · 11
Enhanced recovery after surgery (ERAS) for vascular surgery: an evidence map and scoping review
2023 · Eric A. Apaydin, Karen Woo, et al. · Systematic Reviews · 9
PDF
The Use of Technology in the Clinical Care of Depression: An Evidence Map.
2018 · Eric A Apaydin, Alicia Ruelaz Maher, et al. · PubMed · 9
Evidence map of ductal carcinoma in situ management options
2019 · Kathryn Bouskill, Susanne Hempel, et al. · Menopause The Journal of The North American Menopause Society · 8
Works count: 130
Citation count: 1,274
H-index: 17
I10-index: 22
Year
Topic
Type